Last reviewed · How we verify
prasugrel or ticagrelor
Both prasugrel and ticagrelor are P2Y12 platelet adenosine diphosphate receptor antagonists that inhibit platelet aggregation and reduce thrombotic events.
Both prasugrel and ticagrelor are P2Y12 platelet adenosine diphosphate receptor antagonists that inhibit platelet aggregation and reduce thrombotic events. Used for Acute coronary syndrome (ACS) including ST-elevation myocardial infarction (STEMI) and non-ST-elevation acute coronary syndrome (NSTE-ACS), Prevention of stent thrombosis in patients undergoing percutaneous coronary intervention (PCI).
At a glance
| Generic name | prasugrel or ticagrelor |
|---|---|
| Also known as | Efient, Brilique |
| Sponsor | University of Florida |
| Drug class | P2Y12 receptor antagonist |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Prasugrel and ticagrelor are dual antiplatelet agents that irreversibly (prasugrel) or reversibly (ticagrelor) block the P2Y12 receptor on platelets, preventing ADP-induced platelet activation and aggregation. This mechanism reduces the formation of pathological blood clots in coronary arteries and stents, lowering the risk of myocardial infarction and stent thrombosis in acute coronary syndrome patients.
Approved indications
- Acute coronary syndrome (ACS) including ST-elevation myocardial infarction (STEMI) and non-ST-elevation acute coronary syndrome (NSTE-ACS)
- Prevention of stent thrombosis in patients undergoing percutaneous coronary intervention (PCI)
Common side effects
- Bleeding (major and minor)
- Dyspnea (ticagrelor)
- Bradycardia (ticagrelor)
- Rash
- Gastrointestinal bleeding
Key clinical trials
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
- Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial (NA)
- ARCANGELO (itAlian pRospective Study on CANGrELOr)
- Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors (PHASE4)
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (PHASE4)
- Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- prasugrel or ticagrelor CI brief — competitive landscape report
- prasugrel or ticagrelor updates RSS · CI watch RSS
- University of Florida portfolio CI